326 related articles for article (PubMed ID: 32827580)
1. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
Luo G; Jin K; Deng S; Cheng H; Fan Z; Gong Y; Qian Y; Huang Q; Ni Q; Liu C; Yu X
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188409. PubMed ID: 32827580
[TBL] [Abstract][Full Text] [Related]
2. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer.
Fujimoto Y; Suehiro Y; Kaino S; Suenaga S; Tsuyama T; Matsui H; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Takami T; Nagano H; Sakaida I; Yamasaki T
Oncology; 2021; 99(4):234-239. PubMed ID: 33440396
[TBL] [Abstract][Full Text] [Related]
3. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
4. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
Luo G; Fan Z; Cheng H; Jin K; Guo M; Lu Y; Yang C; Fan K; Huang Q; Long J; Liu L; Xu J; Lu R; Ni Q; Warshaw AL; Liu C; Yu X
Pancreatology; 2018 Dec; 18(8):971-976. PubMed ID: 30131287
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
[TBL] [Abstract][Full Text] [Related]
6. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer.
Banfi G; Zerbi A; Pastori S; Parolini D; Di Carlo V; Bonini P
Clin Chem; 1993 Mar; 39(3):420-3. PubMed ID: 8448851
[TBL] [Abstract][Full Text] [Related]
7. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
8. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
9. Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.
Huang T; Jiang SW; Qin L; Senkowski C; Lyle C; Terry K; Brower S; Chen H; Glasgow W; Wei Y; Li J
Int J Mol Sci; 2015 Jan; 16(2):2956-70. PubMed ID: 25642754
[TBL] [Abstract][Full Text] [Related]
10. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.
Goh SK; Gold G; Christophi C; Muralidharan V
ANZ J Surg; 2017 Dec; 87(12):987-992. PubMed ID: 28803454
[TBL] [Abstract][Full Text] [Related]
11. Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer.
Xu X; Xiao Y; Hong B; Hao B; Qian Y
Cancer Biomark; 2019; 25(3):251-257. PubMed ID: 31282407
[TBL] [Abstract][Full Text] [Related]
12. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.
Jiang JT; Wu CP; Deng HF; Lu MY; Wu J; Zhang HY; Sun WH; Ji M
World J Gastroenterol; 2004 Jun; 10(11):1675-7. PubMed ID: 15162550
[TBL] [Abstract][Full Text] [Related]
13. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.
Aldakkak M; Christians KK; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Evans DB; Tsai S
HPB (Oxford); 2015 Oct; 17(10):942-52. PubMed ID: 26255895
[TBL] [Abstract][Full Text] [Related]
15. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.
Luo G; Guo M; Jin K; Liu Z; Liu C; Cheng H; Lu Y; Long J; Liu L; Xu J; Ni Q; Yu X
Pancreatology; 2016; 16(6):1057-1062. PubMed ID: 27692554
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
[TBL] [Abstract][Full Text] [Related]
18. Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma.
Nurmi AM; Mustonen HK; Stenman UH; Seppänen HE; Haglund CH
Sci Rep; 2021 Jan; 11(1):781. PubMed ID: 33437015
[TBL] [Abstract][Full Text] [Related]
19. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
[TBL] [Abstract][Full Text] [Related]
20. Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.
Tang H; Singh S; Partyka K; Kletter D; Hsueh P; Yadav J; Ensink E; Bern M; Hostetter G; Hartman D; Huang Y; Brand RE; Haab BB
Mol Cell Proteomics; 2015 May; 14(5):1323-33. PubMed ID: 25733690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
